The therapeutic use of this medicine is based on established clinical information for the management of various advanced solid tumors. This therapy is applied across domains where additional symptomatic support is needed for conditions including metastatic colorectal, non-squamous non-small cell lung, ovarian, renal cell cancers, and recurrent glioblastoma.

This therapy is used for managing the effects of systemic disease and supports the overall patient journey by delaying the worsening or spread of the disease, which contributes to easing the overall symptom load when used in combination with chemotherapy. This treatment is considered relevant for easing symptoms that interfere with daily functioning in patients with recurrent or highly metastatic conditions. The use is common across conditions characterized by periods of heightened symptoms (e.g., advanced stages).

This therapy is relevant for easing symptoms linked to increased neurological or muscular activity within recurrent brain tumors, which may assist with maintaining functional stability and easing the impact of challenging neurological symptoms.

---

“This approach may assist with maintaining functional stability and easing the impact of challenging neurological symptoms in advanced cancer.”

---

Quick Fact: Symptoms related to Neurological Activity

This treatment is relevant for easing symptoms linked to organ-specific functional stress.

Who Can and Cannot Use Avastin (Bevacizumab)

Official regulatory documents strictly define the population eligibility for Avastin. The medicine is absolutely contraindicated for patients with known hypersensitivity to bevacizumab, its excipients, or Chinese Hamster Ovary (CHO) cell products. It is also strictly contraindicated for use during pregnancy due to the potential for fetal harm.

Mandatory Exclusions and Discontinuation

Therapy must be permanently discontinued if a patient develops certain severe clinical events. These include gastrointestinal (GI) perforation, a severe arterial thromboembolic event (ATE), hypertensive crisis, or the development of a Grade 4 fistula. Use is also prohibited in patients with a recent history of serious hemorrhage.

Age, Organ Function, and Reproductive Restrictions

Avastin is not approved for patients under 18 years old, as safety and efficacy have not been established in the pediatric population. Use is conditional on the patient's surgical status; treatment must not be initiated until at least 28 days after major surgery and only when the surgical wound is fully healed. Additionally, regulatory documents state that use in patients with renal impairment or hepatic impairment has not been studied. Females of reproductive potential must use effective contraception during treatment and for six months following the final dose.

Interactions with other medicines and products

Official regulatory information regarding Bevacizumab interactions is focused on administration constraints and specific drug combinations, rather than metabolic enzyme pathways.

Interaction Restrictions and Timing Rules

Constraint Type	Official Regulatory Statement
Preparation Prohibition	The product must not be mixed or co-administered with dextrose or glucose solutions due to incompatibility and risk to product stability.
Drug Combination	Co-administration with Panitumumab is not recommended in metastatic colorectal cancer due to an officially documented increased risk of severe toxicity and mortality in clinical studies.
Timing Separation	A mandatory rule requires administration to be discontinued for at least 28 days prior to elective major surgery, and withheld for at least 28 days post-surgery or until complete wound healing.

Pharmacokinetic Interaction Profile

Regulatory studies confirm that the medicine has no clinically relevant pharmacokinetic interaction with commonly co-administered cytotoxic agents, including Irinotecan, 5-Fluorouracil, Cisplatin, and Paclitaxel. The systemic exposure (AUC and Cmax) of Bevacizumab is not altered by these chemotherapy agents, and vice versa. This lack of pharmacokinetic alteration is consistent with the drug being a monoclonal antibody, which is cleared primarily through non-CYP-mediated catabolism. No specific interactions with food, alcohol, or herbal products are documented in official regulatory labeling.

Targeted Blockade of Pro-Angiogenic Signaling

The drug functions as a highly specific inhibitor by binding to the circulating protein Vascular Endothelial Growth Factor A (VEGF-A). This high-affinity neutralization physically prevents the growth factor from activating its receptors (VEGFR-1 and VEGFR-2) on endothelial cells, and inhibits the signal cascade necessary for blood vessel formation.

Suppression of Neovascularization and Vascular Regression

By interrupting the VEGF-A/VEGFR signaling pathway, Avastin actively suppresses the cellular processes—proliferation and migration—that drive angiogenesis and the sprouting of new vessels (neovascularization). This results in the regression of existing abnormal microvessels and prevents the formation of new vasculature, which limits the available blood supply to the tissue.

Regulation of Vascular Permeability

A key secondary effect of VEGF-A neutralization is the resulting reduction of its influence on vascular permeability (leakiness). This mechanism results in the normalization of the microvasculature structure and a decrease in the interstitial fluid pressure within the targeted tissue. This physiological adjustment reduces the flow and supply capacity of the local vasculature.

How Avastin (Bevacizumab) is Used in Clinical Practice

Avastin is exclusively administered as an Intravenous (IV) Infusion by a qualified healthcare professional; there are no approved oral or other routes of administration. Due to its formulation as a sterile concentrate, the product must be diluted prior to infusion using a 0.9% Sodium Chloride solution, and Dextrose (glucose) solutions must not be used for this preparation. The concentrate should also never be shaken.

Dosing and Administration Schedule

The amount of medicine administered is determined precisely based on the patient's body weight and is expressed in milligrams per kilogram (mg/kg). Standard dosing ranges from 5 mg/kg to 15 mg/kg, depending on the specific regimen.

Administration follows a defined, intermittent cyclical schedule. Infusions are typically scheduled once every two weeks or once every three weeks. This cyclical pattern is continued until the end of the planned course of therapy or when disease progression is observed.

Infusion Timing Protocol

To ensure proper administration, a specific timing protocol is followed. The initial IV infusion must be given slowly over a period of 90 minutes. If the initial infusion is well-tolerated, the second infusion may be reduced to 60 minutes. All subsequent infusions may then be administered over the shortest time, typically 30 minutes, provided the previous administrations were tolerated.

No specific dose adjustments are typically required for older adults or for patients with renal or hepatic impairment.

Research Evidence / Overview of Studies for Avastin (Bevacizumab)

This section summarizes the official research conducted to evaluate bevacizumab (Avastin), drawing on findings from large clinical trials and authoritative sources. It describes the scope of existing evidence, the types of outcomes that were measured, and where research is still considered limited or ongoing.

---

Evidence for Use in Metastatic Colorectal Cancer (mCRC)

Research for this type of cancer has primarily focused on large, multi-center Randomized Controlled Trials (RCTs). The key outcomes that were monitored were the Overall Survival (OS) measurement and the Progression-Free Survival (PFS) measurement. Studies reported that OS and PFS measurements were numerically greater for the groups receiving the combination therapy compared to the chemotherapy-alone groups. These data show patterns related to tumor response, noting that a higher percentage of patients were measured as having a reduction in tumor size when the medicine was observed in combination regimens. The results apply only to the populations studied, meaning data for certain groups remain insufficient.

---

Evidence for Use in Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

The research examined this medicine for non-squamous non-small cell lung cancer in large, comparative Phase III trials. The key outcome measured was Overall Survival (OS), with Progression-Free Survival (PFS) also being monitored closely. The results of these pivotal trials describe patterns observed in the studies where patients receiving the combination of chemotherapy and the medicine had numerically greater measured OS and PFS times than those receiving chemotherapy alone. The key regulatory trials excluded patients with specific tumor types (squamous cell histology) due to particular trial design considerations. Therefore, data for that specific subgroup remain insufficient.

---

Evidence for Use in Ovarian, Fallopian Tube, and Peritoneal Cancers

The research for these cancers involved major international Randomized Controlled Trials (RCTs). The main outcome that was evaluated in these trials was the Progression-Free Survival (PFS) measurement. Multiple RCTs consistently reported numerically greater measured Progression-Free Survival times for patients receiving the medicine in the combination and maintenance settings. However, the findings regarding Overall Survival measurements across the entire study population findings were mixed and certainty remains low for a statistically clear difference.

---

What Remains Unaddressed or Uncertain in the Research

A key limitation is the inconsistency of the findings regarding Overall Survival measurements across multiple tumor types (notably ovarian and renal cell cancers), where certainty remains low despite clear findings on Progression-Free Survival. This suggests that while research provides insight into short-term changes or the course of the condition, long-term effects are not fully established in every indication.

Common questions about Avastin Roche (FAQ)

---

Q: How long does it usually take to see results after starting Avastin?

Regulatory documents describing clinical trials primarily focus on long-term outcomes measured over months, such as Overall Survival (OS) and Progression-Free Survival (PFS). Official product information does not define a specific time frame for a patient to observe initial results after starting the medicine.

---

Q: If I get a cut, will it take longer to heal while I'm on Avastin?

Official safety information notes that this medicine is associated with a risk of impaired wound healing and wound dehiscence (a surgical wound opening up). Official regulatory documents state that the medicine should be withheld for at least 28 days before and after major surgery, or until a surgical wound is fully healed, due to the risk of impaired healing.

---

Q: Can I drink alcohol in moderation while on Avastin?

Regulatory labeling focuses on the medicine itself and does not document any specific pharmacokinetic interaction between it and alcohol. This means alcohol is not known to affect how the drug works in the body based on official regulatory data.

---

Q: Why is Avastin not suitable for people who have uncontrolled high blood pressure?

High blood pressure, or Hypertension, is officially listed as a very common adverse reaction associated with the medicine. Official clinical trials used to establish approval generally exclude patients who already have uncontrolled high blood pressure. This limits the available data for this patient group due to the known potential for this adverse effect.

---

Q: What is the difference between an FDA-approved use and other potential uses for Avastin?

The approved uses, or indications, are the specific conditions listed on the official medicine label by government agencies like the FDA. These uses are based on extensive data submitted and reviewed. Any use for conditions not listed on the official label is considered outside of the regulatory scope of approval.

---

Q: What is the process for receiving Avastin, and how long does it take?

The medicine is always administered by a healthcare professional as an Intravenous (IV) infusion. Official administration instructions state that the first infusion is given over a longer period (90 minutes). If that is tolerated, subsequent infusions may be administered over progressively shorter periods, such as 60 minutes and then 30 minutes.

---

Q: Can Avastin be used alone or is it always given with other drugs?

The medicine is generally indicated for most uses in combination with intravenous chemotherapy. Official documents indicate there is at least one official indication where the medicine is approved as a single agent.

---

Q: Does Avastin cause weight gain or weight loss?

Official safety data lists adverse reactions based on their frequency in clinical trials. According to regulatory labeling, neither weight gain nor weight loss is listed among the Very Common or Common adverse reactions.

---

Q: What is the main reason doctors prescribe Avastin?

The medicine is indicated for the treatment of specific types of cancer, including metastatic colorectal, non-squamous non-small cell lung, and certain ovarian cancers. The purpose is to slow tumor growth by interfering with the formation of new blood vessels that feed the tumors.

---

Q: How is Avastin different from other cancer treatments that work on blood vessels?

The medicine is a type of monoclonal antibody that specifically targets and binds to the protein Vascular Endothelial Growth Factor A (VEGF-A) in the circulation. This prevents the protein from activating the receptors that promote new blood vessel growth.

---

Q: Can Avastin affect my ability to drive or operate machinery?

Some officially reported adverse reactions may affect a person's ability to drive or use machinery. For example, fatigue and headache are listed as very common effects. Due to the potential for these side effects, official information advises caution.

---

Q: Does Avastin cause hair loss like traditional chemo?

Official regulatory documents classifying the adverse reactions based on clinical trial frequency do not list hair loss (alopecia) among the Very Common or Common adverse reactions.

---

Q: What if I have an allergic reaction to Avastin? What are the signs?

Infusion-related reactions are officially documented and can include signs such as high blood pressure, trouble breathing, chest pain, headache, and sweating. Severe allergic reactions are noted in the safety information, and treatment may need to be stopped.

---

Q: Why is Avastin sometimes used to treat non-cancer conditions in research?

The medicine is an anti-VEGF agent that inhibits blood vessel growth. Because its mechanism involves regulating the vascular system, it has been studied for uses in specific eye diseases like wet age-related macular degeneration, which involves abnormal blood vessel growth.

---

Q: Is Avastin safe for people with pre-existing heart conditions?

The medicine is associated with a risk of serious adverse reactions, including Congestive Heart Failure (CHF) and Arterial Thromboembolic Events (blood clots in arteries). Because of these potential risks, patients with a significant history of heart disease were often excluded from the official clinical trials.

---

Q: What if I feel symptoms of an infection while I am on Avastin?

Official safety data has noted risks of febrile neutropenia (fever with a low white blood cell count) in some clinical trials, especially when used in combination with chemotherapy. While infection risk is not listed as a universally common adverse reaction, any symptoms of infection should be reported to a healthcare provider.

---

Q: What are the long-term effects of Avastin treatment that research has studied?

Long-term research focuses on measures like Overall Survival (OS) and Progression-Free Survival (PFS), which describe the duration of benefit. Official labeling notes that the evidence regarding Overall Survival across all approved indications remains mixed, suggesting that long-term effects are not fully established for every use.

---

Q: Are there any official registry studies tracking Avastin's long-term safety?

As a government-approved biologic medicine, the product is subject to post-market reporting requirements outlined in federal regulations. These rules mandate the tracking and reporting of adverse events and safety data after the product is made available to the public.

---

Q: Is it common for Avastin to be stopped due to side effects?

Regulatory documents indicate that the medicine is associated with a spectrum of serious adverse reactions, which, if they occur, require permanent discontinuation of treatment. These reactions include Gastrointestinal Perforations, severe Hemorrhage, and severe Wound Healing Complications.

---

Q: What does the term 'combination therapy' mean when talking about Avastin?

The term combination therapy means that this medicine is used in conjunction with other treatments. For most of its official indications, the medicine is administered in combination with other chemotherapy agents rather than being given by itself.

---

Q: Is it normal to feel nauseous right after the infusion?

Official safety data lists Diarrhea as a Very Common adverse reaction, which affects more than 1 in 10 patients. While Nausea is sometimes reported at a higher incidence when the medicine is used in combination with certain chemotherapy regimens, it is not listed as a universally very common side effect.

---

Q: What are the official clinical trial findings regarding Avastin's use in colon cancer?

Official trial findings for metastatic colorectal cancer (mCRC) report that the addition of the medicine to intravenous chemotherapy resulted in numerically greater measurements of Overall Survival (OS) and Progression-Free Survival (PFS) compared to chemotherapy alone. These measurements were the primary focus of the regulatory studies.

Storage and Disposal of Avastin (Bevacizumab)

The storage and handling of Avastin concentrate are strictly defined by regulatory requirements to maintain the integrity of this biologic medicine.

Mandatory Storage Conditions

The unopened vial must be stored under refrigeration at a temperature between 2°C and 8°C (36°F and 46°F). The product must be stored in the original outer carton to protect it from light, and the vial must not be frozen.

Stability and Handling Rules

Since Avastin contains no antimicrobial preservative, the diluted solution should be used immediately. If immediate use is not possible, the solution may be stored for a maximum of 24 hours at 2°C to 8°C, provided the dilution was performed under validated aseptic conditions.

Disposal and Safety

Avastin must be kept out of the sight and reach of children. Any unused product or waste material must be disposed of in accordance with local requirements for pharmaceutical waste.